Scarica l'app Stockscreener
5.21
3.34%
-0.18
Dopo l'orario di chiusura:
5.21
Corvus Pharmaceuticals Inc Borsa (CRVS) Ultime notizie
Corvus Pharmaceuticals to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference - The Manila Times
Exclusive Healthcare Insights: Corvus Pharma Takes Center Stage at Major Oppenheimer Conference - StockTitan
JPMorgan Chase & Co. Buys 40,404 Shares of Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) - Defense World
Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Receives $12.38 Average Target Price from Analysts - Defense World
Analysts Set Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) PT at $12.38 - MarketBeat
Cantor Fitzgerald Comments on CRVS FY2025 Earnings - Defense World
When (CRVS) Moves Investors should Listen - Stock Traders Daily
Equities Analysts Offer Predictions for CRVS FY2025 Earnings - MarketBeat
CRVS’s Stock Market Adventure: -8.04% YTD Growth Amidst Volatility - The InvestChronicle
Corvus Pharmaceuticals (NASDAQ: CRVS) Announces Positive Interim Data from Phase 1 Clinical Trial of Soquelitinib for Atopic DermatitisOn January 13, 2025, Corvus Pharmaceuticals, a clinical-stage biopharmaceutical company, released encouraging int - Defense World
HC Wainwright Reiterates "Buy" Rating for Corvus Pharmaceuticals (NASDAQ:CRVS) - MarketBeat
HC Wainwright & Co. Initiates Coverage of Corvus Pharmaceuticals (CRVS) with Buy Recommendation - MSN
Corvus Pharmaceuticals Reports Promising Interim Data on Soquelitinib - TipRanks
Corvus reports hopeful data on eczema drug trial - Investing.com India
Corvus reports hopeful data on eczema drug trial By Investing.com - Investing.com Australia
Corvus Pharmaceuticals Announces Data from Cohort 2 of - GlobeNewswire
Corvus Pharmaceuticals Announces Data from Cohort 2 of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis - Yahoo Finance
50,221 Shares in Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Bought by Jane Street Group LLC - Defense World
Geode Capital Management LLC Purchases 102,869 Shares of Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) - MarketBeat
Geode Capital Management LLC Increases Stake in Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) - Defense World
Corvus Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference - The Manila Times
Corvus Pharmaceuticals CEO to Present Corporate Overview at J.P. Morgan Healthcare Conference - StockTitan
We're Not Worried About Corvus Pharmaceuticals' (NASDAQ:CRVS) Cash Burn - Yahoo Finance
What is HC Wainwright’s Forecast for CRVS FY2024 Earnings? - Defense World
What is HC Wainwright's Forecast for CRVS FY2024 Earnings? - MarketBeat
Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Receives $12.83 Consensus Price Target from Analysts - Defense World
Analysts Set Expectations for CRVS Q4 Earnings - Defense World
Drug Innovator Launches Pivotal Cancer Trial Breakthrough - Streetwise Reports
What is HC Wainwright's Estimate for CRVS Q4 Earnings? - MarketBeat
State Street Corp Purchases 57,943 Shares of Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) - Defense World
Corvus Pharmaceuticals (NASDAQ:CRVS) Now Covered by Analysts at HC Wainwright - Defense World
Corvus wins new buy from H.C. Wainwright despite recent selloff - MSN
Corvus stock wins new buy at H.C. Wainwright (CRVS:NASDAQ) - Seeking Alpha
Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Receives Average Recommendation of "Buy" from Analysts - MarketBeat
This Kopin Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday - Benzinga
Corvus Pharmaceuticals (NASDAQ:CRVS) Coverage Initiated at HC Wainwright - MarketBeat
When the Price of (CRVS) Talks, People Listen - Stock Traders Daily
XTX Topco Ltd Buys Shares of 14,086 Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) - Defense World
Corvus falls after early-stage data for eczema therapy - MSN
Corvus Pharmaceuticals (NASDAQ:CRVS) Announces Interim Data from Atopic Dermatitis TrialBURLINGAME, Calif. – Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS) disclosed key interim data from its randomized, double-blind, placebo-controlled Phase 1 cl - Defense World
Corvus: Early Atopic Dermatitis Data Signals More Questions Than Answers (Rating Downgrade) - Seeking Alpha
Corvus Pharmaceuticals Target of Unusually High Options Trading (NASDAQ:CRVS) - Defense World
Why Is Corvus Pharmaceuticals Stock Trading Lower On Wednesday? - AOL
Corvus Pharmaceuticals: Not Just A One-Hit Wonder In ITK Inhibitor Targeting (CRVS) - Seeking Alpha
Crude Oil Gains Over 1%, General Mills Shares Fall - Benzinga
Dow Surges 150 Points, US Current Account Deficit Widens In Q3 - Benzinga
Stock Traders Buy High Volume of Put Options on Corvus Pharmaceuticals (NASDAQ:CRVS) - MarketBeat
Corvus stock falls after eczema trial data (CRVS:NASDAQ) - Seeking Alpha
Heico, Corvus Pharmaceuticals, Tesla And Other Big Stocks Moving Lower In Monday's Pre-Market Session - Benzinga
Corvus Pharmaceuticals Reports Promising Phase 1 Data and Financial Boost - TipRanks
Corvus Pharmaceuticals Shares Surge 7% After Positive Phase 1 Trial Results for Soquelitinib in Atopic Dermatitis - mediahousepress
Corvus Pharmaceuticals stock falls despite promising early trial results - Investing.com
1.03%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):